Alembic Pharmaceuticals and Aurobindo Pharma are recalling products in the US due to manufacturing problems. Alembic is recalling 82,400 bottles of Tobramycin Ophthalmic Solution due to “Failed Impurities/Degradation Specifications.” Meanwhile, Aurobindo Pharma is recalling 48 bottles of Rufinamide …

Alembic, Aurobindo recall drugs in US market

Alembic Pharmaceuticals plans to launch 20 new products in the US market in FY24, including oncology and non-oncology injectables, derma, and ophthalmic products. The launches will be facilitated by the newly USFDA-compliant facilities. The company also plans to take advantage of drug shortages in t…

Alembic aims for US rebound with new launches

ICICI Securities recommended reduce rating on Alembic Pharma with a target price of Rs 705 in its research report dated August 07, 2023.

Reduce Alembic Pharma; target of Rs 705: ICICI Securities

Alembic Pharma Q1 revs beat JMFe, PAT beat due to lower dep & tax. Management guides to outperform IPM by 4-5 ppt. US performance below estimates. CWIP impaired, new facilities to cushion op. expenses. Upgrade to BUY, key triggers: US base improvement, margin expansion & capital allocation strategy.…

Broker’s call: Alembic Pharma (Buy)

Launch momentum is critical for U.S. growth; domestic business growth to remain steady.

Alembic Pharma Q1 Results Review - Execution Remains A Key: Dolat Capital

Alembic Pharmaceuticals share price has been on an uptrend since March. It closed above ₹700 on Thursday. Support at ₹720 and ₹710-707. Buyers likely on dips. Expect share price to reach ₹800-820 in 3-4 weeks. Go long now, accumulate at ₹722. Stop-loss at ₹702, trail up to ₹738, then ₹770, exit at ₹…

Stock to buy today: Alembic Pharmaceuticals (₹732.15)

Alembic Pharmaceuticals has received establishment inspection report for solid oral formulation facility at Jarod, Gujarat

Alembic receives USFDA nod for Jarod plant

Among the popular names, the consolidated net profit of Alembic Pharmaceuticals surged 596 per cent to Rs 152.60 crore in Q4FY23 against Rs 21.92 crore in the same quarter a year ago.

Smallcap shares: Well-known firms clocked over 100% jump in Q4 profit; should you buy stocks?

KR Choksey is bullish on Alembic Pharma has recommended buy rating on the stock with a target price of Rs 704 in its research report dated May 06, 2023.

Buy Alembic Pharma; target of Rs 704: KR Choksey

Motilal Oswal recommended Neutral rating on Alembic Pharma with a target price of Rs 550 in its research report dated May 06, 2023.

Neutral Alembic Pharma; target of Rs 550: Motilal Oswal

Alembic Pharmaceuticals Limited, on Friday, posted over three-fold jump in standalone net profit for the quarter ended March 31, 2023, at ₹131 crore, up from ₹42 crore in the same quarter last year, supported by reduction in total expenses

Alembic Pharmaceuticals Q4 net jumps three-fold at ₹131 cr

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Alembic Pharmaceuticals Limited is a pharmaceutical company engaged in developing formulations and active pharmaceutical ingredients (API).